Clinical Trial Update: A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4 [Phase 1]

View source ↗

Summary

A randomized Phase 1 dose-escalation study evaluating subcutaneous RUC-4 in coronary artery disease has completed, providing early safety and pharmacokinetic da…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• RUC-4

Snippet

Sponsor: CeleCor Therapeutics | Conditions: Coronary Disease | Phase 1 | Status: COMPLETED